{"schema_version":"secwatch.filing_event.v1","accession":"0001299130-23-000047","form_type":"8-K","ticker":"PACB","cik":"0001299130","company_name":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC.","filed_at":"2023-05-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.309848+00:00","generated_at":"2026-06-16T02:52:43.791416+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"PacBio reports record Q1 revenue $38.9M (+17% YoY) but net loss widens to $88.0M","bullets":["Q1 revenue $38.9M (+17% YoY); net loss $88.0M ($0.36 loss per share) vs $81.5M loss prior year.","Shipped 38 sequencing systems (32 Revio, 6 Sequel IIe); Revio launch exceeding expectations with record backlog.","GAAP gross margin fell to 25% from 43% YoY due partly to $3.5M charge for excess Sequel II/IIe consumables.","Cash and investments $874.9M at March 31 vs $772.3M at Dec 31, 2022.","Received first orders for Onso short-read system; introduced new workflows and DNA extraction kits."],"urls":{"canonical":"https://secwatch.observer/filing/0001299130-23-000047","json":"https://secwatch.observer/filing/0001299130-23-000047.json","markdown":"https://secwatch.observer/filing/0001299130-23-000047.md","text":"https://secwatch.observer/filing/0001299130-23-000047.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1299130/000129913023000047/0001299130-23-000047-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1299130/000129913023000047/pacb-20230502.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T02:52:43.791416+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"21f2007a2548ba33c1ec8b70a2d8cc77102fba33","claim":"PACIFIC BIOSCIENCES OF CALIFORNIA, INC. reported the quarter ended March 31, 2023 results: revenue $38.9 million, net income Net loss for the first quarter of 2023 was $88.0 million, EPS Net loss per share for the first quarter of 2023 was $0.36.","evidence_excerpt":"Quarter 2023 Menlo Park, Calif. – May 2, 2023 – PacBio (NASDAQ: PACB) today announced financial results for the quarter ended March 31, 2023. First quarter results • Revenue of $38.9 million, a 17% increase compared with $33.2 million in the prior year period. • Shipped 38 sequencing systems in the first quarter, including 32 Revio systems and 6 Sequel IIe systems. •","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1299130/000129913023000047/0001299130-23-000047-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2023"},{"label":"Revenue","value":"$38.9 million"},{"label":"Net income","value":"Net loss for the first quarter of 2023 was $88.0 million"},{"label":"EPS","value":"Net loss per share for the first quarter of 2023 was $0.36"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}